🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “Agios” Clear

  1. AG-348

    Agios Netherlands B.V.

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

  2. AG-348 Sequence A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. AG-519

    Agios Netherlands B.V.

    Anemia

    phase 1 small molecule terminated

    1 trial

  4. AG-636

    Agios Netherlands B.V.

    Lymphoma

    phase 1 small molecule terminated

    1 trial

  5. AG-881

    Agios Netherlands B.V.

    Healthy Male Participants

    phase 1 small molecule completed

    1 trial

  6. AG-881

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  7. AG-946

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. AG120

    Agios Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    2 trials

  9. AG221

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. AG881

    Agios Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule completed

    1 trial

  11. AG881

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. AG881 Formulation 1

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. Ivosidenib

    Agios Netherlands B.V.

    IDH1 Mutation Myeloid Neoplasms

    phase 1 small molecule completed

    1 trial

  14. Mitapivat

    Agios Netherlands B.V.

    Moderate Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  15. Mitapivat

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  16. Mitapivat tablet

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. Mitapivat tablets

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. Placebo for Treatment A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. [14C]-AG-120

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. [14C]-tebapivat

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  21. itraconazole

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  22. ivosidenib (AG-120)

    Agios Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  23. Mitapivat

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    approved small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources